Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 03, 2023

Overall Survival and Exploratory Biomarker Analyses in Patients With HR+/HER2+ Metastatic Breast Cancer Receiving Abemaciclib Plus Trastuzumab ± Fulvestrant vs Trastuzumab Plus Chemotherapy

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients
Clin. Cancer Res 2023 Oct 31;[EPub Ahead of Print], SM Tolaney, S Goel, J Nadal, H Denys, MR Borrego, LM Litchfield, J Liu, AK Appiah, Y Chen, F Andre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading